Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 16 Jun, 07:07 pm

Agios Pharmaceuticals (NASDAQ: AGIO) received a reiterated Buy rating and an increased price target of $54.00 from H.C. Wainwright, reflecting strong analyst confidence. Positive Phase 3 clinical trial results for mitapivat in Sickle Cell Disease demonstrated statistically signif

Analyst Confidence & Price Targets: Analysts from Robert W. Baird and Evercore ISI have set optimistic price targets of $160.00 and $185.00 for Roku, respectively, driven by positive outlooks and product enhancements. Market Surge & Valuation: Roku's stock experienced a 20.10% si
Headlines provided by Investing.com